VKTX - Viking Therapeutics, Inc.
| Previous Close | 8.34 |
| Open | 8.40 |
| Bid | 8.52 x 1800 |
| Ask | 8.55 x 900 |
| Day's Range | 8.32 - 8.55 |
| 52 Week Range | 4.86 - 24.00 |
| Volume | 1,256,219 |
| Avg. Volume | 3,126,958 |
| Market Cap | 615.287M |
| Beta (3Y Monthly) | 3.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.36 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.13 |
- Motley Fool•8 days ago
3 Small-Cap Biotech Stocks You Can Buy Right Now
They're risky. You'll have to wait years before any significant revenue comes in. But these biotech stocks could be huge winners.
- Simply Wall St.•11 days ago
Have Insiders Been Buying Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Insider Monkey•16 days ago
Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?
We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
- Thomson Reuters StreetEvents•17 days ago
Edited Transcript of VKTX earnings conference call or presentation 2-May-19 8:30pm GMT
Q1 2019 Viking Therapeutics Inc Earnings Call
- Motley Fool•18 days ago
3 Top Biotech Stocks to Buy in May
These three biotech stocks could be prime comeback candidates.
- Zacks Small Cap Research•21 days ago
VKTX: Pre-IND Meeting with FDA in Summer 2019; Phase 2b NASH Trial to Initiate 2H19…
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). While details of the trial have yet to finalized, we do anticipate the trial including biopsy-confirmed NASH patients with F2 and F3 fibrosis (although there are likely to be a small number with F1 fibrosis). Regarding the upcoming trial, based on the length for competitors Phase 2b trials we estimate that if started in the second half of 2019 topline data would probably be available in the first half of 2021, although 4Q20 isn’t out of the question.
Motley Fool•22 days agoViking Therapeutics Inc (VKTX) Q1 2019 Earnings Call Transcript
VKTX earnings call for the period ending March 31, 2019.
- PR Newswire•22 days ago
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily - Phase 2b Study of VK2809 ...
- PR Newswire•25 days ago
Viking Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , April 30, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- Motley Fool•28 days ago
2 Reasons Gilead Sciences' NASH Program Could Bounce Back
It's been a rough few years, but an unexpected partnership could put the biotech's liver disease program back on top.
- PR Newswire•last month
Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
Conference Call Scheduled for Thursday, May 2 at 4:30 p.m. Eastern Time SAN DIEGO , April 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
- Market Realist•last month
VKTX or ENTA: What to Expect from Revenue Growth in 2019
What Are Analysts Recommending for VKTX and ENTA?(Continued from Prior Part)Growth drivers In November 2018, Viking Therapeutics (VKTX) issued a press release announcing positive results from its Phase 2 trial evaluating the efficacy of the 1-mg dose
- Market Realist•last month
What Are Analysts Recommending for VKTX and ENTA?
What Are Analysts Recommending for VKTX and ENTA?Stock price movementOn April 12, Viking Therapeutics (VKTX) closed at $9.35, 6.22% lower than its previous closing price, 153.39% higher than its 52-week low of $3.69, and 61.04% below its 52-week
- Zacks Small Cap Research•last month
VKTX: VK2809 5 mg Data Presented at EASL…
In addition, all nine patients in the 5 mg cohort experienced ≥ 30% reduction in liver fat and 77.8% were ‘super-responders’, defined as experiencing ≥ 50% reduction in liver fat. For those who may argue that the two patient populations are too dissimilar to offer a valid comparison, we believe that the very similar placebo responses seen in both outcomes in the table below indicate that the two populations are in fact quite similar.
- PR Newswire•last month
Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Patients Receiving 5 mg Daily Doses of VK2809 Demonstrated Statistically Significant Median Reduction in Liver Fat Content of 53.8% 88% of Patients Receiving VK2809 Experienced ≥ 30% Reduction in Liver ...
- Motley Fool•2 months ago
Why Viking Therapeutics Stock Perked Up in March
Viking's shares received a boost from a pair of catalysts last month.
- Motley Fool•2 months ago
Here's Why Investors Are Betting Against These 2 Biotech Stocks
Are intrepid short-sellers taking advantage of misguided enthusiasm?
- PR Newswire•2 months ago
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
Late-Breaker Presentation to Highlight Efficacy, Safety and Tolerability Results from 12-Week Phase 2 Trial Including New Data from Study's 5 mg Treatment Arm SAN DIEGO , April 4, 2019 /PRNewswire/ -- Viking ...
- Motley Fool•2 months ago
3 Top Value Stocks to Buy Right Now
Bargain hunting? These out-of-favor biotech and e-commerce stocks should appeal to value investors.
- TheStreet.com•2 months ago
The Best Approach to Trading Lyft
Every day this week the indices have opened on an upbeat note and then sold off. If you are interested in trading it the best approach is to wait at least 30 minutes to an hour after it opens and watch for a trading range to develop. The trading range provides a mechanism for risk control and nothing more.
- Market Realist•2 months ago
Analysts Are Mostly Positive on Viking Therapeutics in March
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 200.82% for Viking Therapeutics (VKTX) based on the company’s closing
- MarketWatch•2 months ago
Harry Boxer: 3 biotech stocks with momentum
Biotech stocks dominate our list of top charts to watch today. The stock is up over 50% this month, and over 400% since the start of the year, as investors await important clinical trial results on the company’s treatment for depression. Invitae Corp. (NVTA) rose 71 cents to $25.75 on 1.2 million shares Thursday.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of VKTX earnings conference call or presentation 13-Mar-19 8:30pm GMT
Q4 2018 Viking Therapeutics Inc Earnings Call
